Ventricular bigeminy and trigeminy caused by hypophosphataemia during diabetic ketoacidosis treatment: a case report

Konrad Miszczuk 1, Joanna Mroczek-Wacinska 1, Robert Piekarski 1, Beata Wysocka-Lukasik 1, Renata Jawniak 2 and Iwona Ben-Skowronek 1*

Abstract

Background: Hypophosphatemia has many causes, and is often encountered during DKA (Diabetic Ketoacidosis) treatment. However, it rarely requires clinical intervention.

Case presentation: Ventricular arrhythmia was observed in a 10-year-old girl with newly diagnosed type 1 diabetes mellitus and hypophosphatemia while undergoing treatment for ketoacidosis. Oral phosphate supplementation ceased ventricular arrhythmia almost completely.

Conclusions: The clinical signs of hypophosphatemia are potentially life-threatening. Therefore, physicians should be vigilant when treating patients who are at risk of hypophosphatemia. Severe hypophosphatemia accompanied by clinical symptoms requires oral or intravenous supplementation of phosphate.

Keywords: Diabetic ketoacidosis, Hypophosphatemia, Ventricular arrhythmia, Case report

Background

Diabetic ketoacidosis (DKA) is a life-threatening condition that requires immediate treatment. Type 1 diabetes mellitus is an autoimmune disease, in which beta-cell destruction process starts as cellular reaction that leads to beta-cell damage that stimulates autoimmune humoral reaction. As the level of anti-pancreatic autoantibodies rises, insulin secretion is impaired leading to complete lack of insulin. As a result, hyperglycemia occurs and leads to ketoacidosis. The initial symptoms such as polydipsia, polyuria and nocturia lead to dehydration. As acidosis progresses, the patient presents elevated heart rate, elevated breathing rate and Kussmaul breathing pattern occurs. These symptoms are often accompanied by stomach ache, nausea and vomiting. As condition worsens, neurological symptoms, ranging from confusion and sleepiness to coma, may occur. The laboratory criteria for DKA diagnosis are: Hyperglycemia (plasma glucose > 200 mg/dL), serum pH < 7.3 or serum bicarbonate level < 15 mmol/L and also the presence of serum ketones and ketonuria. DKA severity is determined by the level of acidosis: in mild DKA pH is 7.2–7.3 or bicarbonate level is 10–15 mmol/L; in moderate DKA pH is 7.1–7.2 or bicarbonate level is 5–10 mmol/L; in severe DKA pH < 7.1 or bicarbonate level < 5 mmol/L. Essential treatment requires fluid resuscitation and human recombinant insulin administration in continuous IV infusion. Patient overall condition should be monitored continuously, blood glucose and neurological status should be checked every hour, serum electrolytes should be checked every 2 h after starting IV fluids. Additionally ECG should be monitored for abnormal T waves and T waves changes. Cerebral edema and hypokalemia are the most common complications during DK treatment. Other possible complications include severe hypophosphatemia, hypocalcaemia, hypomagnesaemia, hypoglycemia, heart arrhythmias, deep vein thrombosis, pulmonary embolism, sepsis, pulmonary edema, acute respiratory distress syndrome, rhabdomyolysis, ischemic renal necrosis, acute renal failure, acute pancreatitis [1].

Phosphorus is an element which is essential for life. The human body contains 11 to 14 g/kg of lean body

* Correspondence: skowroneki@interia.pl
1Department of Pediatric Endocrinology and Diabetology, Medical University of Lublin, Lublin, Poland
Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
mass [2]. The majority of phosphorus is concentrated in the bones (600–700 g), and is also found in the soft tissue (100–200 g). Apart from its structural function, it plays a crucial role in cellular metabolism and in cell membranes. Phosphorus is a part of adenosine triphosphate (ATP), phosphocreatine and 2,3-diphosphoglycerate (2,3-DPG) [3].

Food is a rich source of phosphorus, especially dairy products, meat and beans. It is estimated that 1 ml of milk contains 1 mg of phosphorus. A typical diet provides 800–1400 ng of phosphorus daily, and approximately 65% of ingested phosphorus is absorbed in the intestines [4, 5].

The normal serum concentration of phosphate fluctuates with age, with the normal concentration for adults ranging between 0.8 and 1.3 mmol/L. Mild hypophosphatemia is defined as a phosphate level between 0.32 and 0.65 mmol/L, while severe hypophosphatemia is diagnosed when the phosphate level drops below 0.32 mmol/L [6].

A shift in phosphate level is expected to occur in DKA, resulting both from the pathogenesis of the disease and insulin action. Although changes in serum phosphate level are widely described [7, 8], there is still need for studies on large research group in that matter. T.Shen and S.Braude evaluated 64 patients with DKA. 63% of the patients had hyperphosphatemia on admission, 33% of the patients had phosphate level within the normal range and 5% of the patients suffered from hypophosphatemia. The phosphate level decreased during DKA treatment in all cases. In 90% nadir was < 0.8 mmol/L, in 36% nadir was < 0.5 mmol/L and severe hypophosphatemia (phosphate level below 0.32 mmol/L) developed in 11% of the cases [9].

There are multiple issues related to the interpretation of serum inorganic phosphorus (Pi) levels. Firstly, there is no simple translation of serum phosphate levels to the severity of clinical signs [6]. Secondly, there is diurnal variation in serum phosphate levels. Finally, hypophosphatemia does not necessarily reflect a deficit in total body phosphorus content, as the intracellular content is 100-times higher than the serum level. It is important to take into consideration that the clinical condition of the patient depends on the intracellular concentration of phosphate [6]. Clinically symptomatic hypophosphatemia is more likely to occur in patients who are nil by mouth, those with impaired food absorption, patients with abnormal intracellular-extracellular phosphate distribution, and patients who lose phosphates via urinary excretion [2, 4] (Table 1).

The life-threatening clinical manifestations of hypophosphatemia are associated with the energetic role of phosphate. As a part of ATP, phosphate is a key element in cell energy turnover. Furthermore, 2,3-DPG deficiency in red blood cells promotes oxygen binding to hemoglobin, therefore oxygen is less likely to be released to the tissues that need it most. Ischemia occurs as a result, which affects both tissues and organs.

The main clinical manifestations of hypophosphatemia include metabolic encephalopathy (including signs of irritability, paraesthesia, seizures, coma), impaired cardiac contractility (including cardiomyopathy), heart arrhythmia (ranging from atrial fibrillation to PVC - Premature Ventricular Contractions), respiratory failure, impaired skeletal muscle contractility (starting from proximal to distal), rhabdomyolysis, dysphagia and hemolysis [1, 2, 4, 10–14].

### Table 1 Causes of hypophosphatemia

| Insufficient inorganic phosphate delivery with food |
|-----------------------------------------------|
| - Premature birth |
| - Anorexia nervosa |
| - Parenteral feeding with a low-phosphorus diet |
| - Drug-binding phosphates |
| - Alcohol addiction |
| An abnormal shift of inorganic phosphate (Pi) from the extracellular space to the intracellular space |
| - Insulin and glucose infusion |
| - Refeeding syndrome |
| - Hungry bones syndrome |
| - Complete parenteral feeding |
| - Anabolic state in patient with severe burn or trauma |
| - Respiratory alkalosis |
| - Tumor progression |
| - Bone marrow transplant |
| Inappropriate urinary phosphate excretion |
| - Hypophosphatemic rickets |
| - Tumor-induced rickets |
| - Fanconi syndrome |
| - Vitamin D deficiency |
| - Glucocorticosteroid overdose tubular acidosis |
| - PTH (parathormone) excess |
| - Presence of PTHrP (Parathyroid hormone-related protein) |

### Case report

A 10-year-old girl was admitted to our clinic due to ketoacidosis associated with newly diagnosed type 1 diabetes. Prior to admission, she had suffered from polyuria, polydipsia, and nocturia for about 2 weeks, and presented with fatigue, drowsiness and a lack of appetite for the last two days. Her history did not include any chronic diseases, and she had normal growth and development.

On admission, she was in a serious state, suffering from vomiting and dehydration, and displaying Kussmaul breathing, a respiratory rate of 45 breaths/min and
tachycardia. The blood test revealed a blood glucose level of 26.8 mmol/L (482 mg/dl), pH 6.902, base excess (BE) of −29.3 mmol/L, HbA1c of 12.9%, sodium level of 142 mEq/L, potassium level of 4.11 mEq/L and ketone level of 6.1 mmol/L. The patient was treated according to the recommendations of the International Society of Pediatric and Adolescent Diabetes and the Polish Diabetes Association [1, 15].

Initially the patient received 500 ml of 0.9% NaCl IV infusion. Next, a continuous IV infusion of short acting insulin was commenced with 2.5 U/h dose, taking into consideration that the patient weight was 40 kg. IV Insulin infusion was sustained for 51 h with dosages ranging from 1.5 U/h to 4 U/h. Overall the patient received 81,75 units of IV insulin during the first 24 h of treatment. Moreover, potassium was supplemented intravenously accordingly to changes in electrolytes results. Although she remained in a serious condition during the first 24 h of treatment, she stopped vomiting and showed gradual improvement in blood test results, with pH normalization and a decrease in the level of ketones. The glucose level was maintained between 8.3 and 13.9 mmol/L (150–250 mg/dl) with intravenous insulin and glucose infusions. The neurological status was checked hourly, and was reported as stable. An ECG was performed within the first few hours of admission, which did not reveal any crucial abnormalities aside from tachycardia. The patient received 65 units of IV insulin during the second 24 h of treatment. During the whole continuous insulin infusion the patient fluid input was 7850 ml (4850 ml IV, 3100 ml orally) and diuresis was 3400 ml.

The patient’s overall condition improved during the second day of treatment, despite the fact that she was still receiving intravenous insulin. That day irregular heartbeats were noticed on auscultation during the physical examination and on the ECG monitor. A second ECG showed premature ventricular complexes (PVCs; also known as trigeminy) with LBBB (left bundle branch block) morphology and a normal axis (Fig. 1). Continuous ECG monitoring was subsequently implemented, and the patient underwent a cardiac consultation. The echocardiogram showed no abnormalities in the structures of the heart and great vessels. The consultant cardiologist confirmed the diagnosis of ventricular arrhythmia (PVCs). The blood results revealed hypokalemia (nadir at 2.9 mmol/L) and hypophosphatemia (nadir at 0.45 mmol/L).

The ECG performed after the first recognition of the patient’s the irregular heart rhythm (Fig. 1) showed: sinus rhythm at 100/min, normal cardiac axis, with premature ventricular complexes. Normal PQ interval (0.14 s), normal QRS duration (0.08 s), normal QT interval (0.31 s) and QTc 0.40 QTd 0.04 s. Normal T wave and repolarization. The biochemistry results at that moment were: Na 134 mmol/L, Na 134 mmol/l [132–145]; K 3.56 mmol/l [4.1-5.3]; Ca 2.70 mmol/l [2.1-2.6]; Mg 0.83 mmol/l [0.53-1.11]; Phosphate 0.45 mmol/l [1.1-2.0] (assessed for the first time); pH 7.34 [7.35-7.45]; BE -11.5 mmol/l [-2.0/+ 3.0]; HCO3 14.2 mmol/l [22.5-30.0]. CK level was not determined. The pattern visible in the ECG was not typical of hypokalemia, which is connected with initial T-wave decrease, followed by ST-segment depression, T-wave inversion, PR interval prolongation and increased P-wave amplitude, observed with further decreases in serum potassium levels. Severe hypokalemia may be associated with giant U-waves created by T- and U-wave fusion. Tachyarrhythmia and rarely atrioventricular block may evolve [16–18]. In our case we did not observe such abnormalities typical to low potassium level in the ECG. Moreover, the ECG was not typical of hypercaemia, which causes prolonged PQ interval and shortening of QT interval [19, 20]. Taking above into consideration we propose possible association between hypophosphatemia and premature ventricular complexes reported in the ECG.

Potassium was supplemented both orally and intravenously. Overall the patient received 123 mEq of potassium during the continuous insulin therapy. As far as phosphorus is concerned, the patient was fed with liquid dairy products that were rich in phosphate, as she was only able to swallow small amounts of non-solid foods due to odynophagia. She was also started on oral phosphate supplementation (phosphate mixture containing

---

**Fig. 1** An electrocardiogram with premature ventricular complexes performed after the first recognition of the irregular heart rhythm.
17.8 g Na₂HPO₄ and 4.88 g NaH₂PO₄ in 100 ml of distilled water, containing 1.6 mmol of inorganic phosphate per 1 ml). As 1 mmol of inorganic phosphate weighs 31 mg, our patient was receiving 62 mg P/Kg body weight every 24 h from the phosphate mixture. She continued to present an irregular heart rate, thus a 24-h ECG Holter monitor examination was performed. The results showed 38,000 monomorphic PVCs, 1615 occurrences of ventricular bigeminy, 1230 of ventricular trigeminy and 453 of ventricular quadrigeminy, which comprised 38% of all the heart electrical activity recorded.

The patient was started on intensive subcutaneous insulin regimen at the 3 day of treatment, after the biochemistry results improved. In the beginning she was receiving 15 units of ultra-long acting basal insulin and 27.5 units of rapid acting insulin for meals and correction doses.

The patient's serum phosphate level normalized over the few next days of treatment (Table 2), and ventricular arrhythmia ceased almost completely. Subsequent ECG Holter examination showed 1760 PVCs, 13 episodes of ventricular bigeminy and 79 episodes of ventricular trigeminy. Additionally, we noticed hypocalcaemia after 3 days of phosphate supplementation. Taking into consideration the patient's severe vitamin D3 deficiency (25(OH)D3 level 9.83 ng/ml), we supplemented both calcium and vitamin D3.

Gradually the patient regained insulin sensitivity and entered a partial remission phase. C-peptide level was 0.84 ng/ml.

The patient was discharged in an overall good condition receiving intensive functional insulin therapy. The regimen included 10 units of basal insulin administered once daily in the evening and rapid acting insulin with insulin: carbohydrate ratio set for each meal and also with recommended correction doses.

A cardiac check-up at the outpatient clinic following discharge revealed no signs of cardiac arrhythmia. The patient is currently on an insulin pump therapy regimen, and her growth and development are within the normal range.

Discussion

The case presented here involved multicausal hypophosphatemia. Diabetic ketoacidosis led to a loss in body phosphorus content. This occurred firstly due to osmotic diuresis, resulting in urinary phosphate loss [9]. Secondly, insulin therapy is known to directly cause a reduction in serum phosphate levels [21]. In addition, variations in the acid-base balance also contribute to hypophosphatemia as, when the pH increases, an intracellular shift of phosphate from the serum takes place [22]. In our patient, vitamin D3 deficiency was another factor that contributed to the low total body phosphate stores [23]. Moreover, the loss of appetite caused a significant decrease in oral phosphate intake. As the patient began eating on the second day of treatment, refeeding syndrome had to be taken into consideration. Taken together, each of these factors contributed to the occurrence of ventricular arrhythmia, despite the serum phosphate level of 0.46 mmol/L not meeting the criteria for severe hypophosphatemia.

We believe that the clinical manifestations of hypophosphatemia were caused not only by the serum phosphate level, but also by a low intracellular phosphate content.

Heart arrhythmias are rare complication of DKA so there is lack of large-group research on that topic. The data available depicts case reports with supraventricular tachycardia (SVT), ventricular tachycardia and atrial fibrillation, which authors describe as multi etiological [24–29].

Arrhythmia associated with hypophosphatemia are mainly supraventricular arrhythmia, and may also include single preliminary ventricular complexes, ventricular bigeminy and trigeminy [30]. Ventricular extrasystoles are considered an early marker of myocardial ischemia [30, 31]. In our case, ventricular arrhythmia ceased almost completely after oral phosphate supplementation and normalization of serum phosphate levels.

Many authors [1, 2, 5, 15] have reported that administration of phosphates in DKA does not improve prognosis, and indeed increases the risk of hypocalcaemia. In our case, hypocalcaemia occurred on the fifth day of treatment, and the patient was treated with calcium supplementation. Routine administration of phosphates in DKA is not recommended. The only indication for the use of phosphates is severe hypophosphatemia

| Day of treatment | Day 1 | Day 2 | Day 3 | Day 5 | Day 6 | Day 7 | Day 8 | Normal range |
|------------------|-------|-------|-------|-------|-------|-------|-------|--------------|
| Natrium (mmol/L) | 142   | 134   | 142   | 139   | 144   | 144   | 141   | 132–145      |
| Potassium (mmol/L) | 4.11  | 3.56  | 4.02  | 2.92  | 3.15  | 3.89  | 4.29  | 4.1–5.3      |
| Calcium (mmol/L) | 2.10  | 2.70  | 2.42  | 2.20  | 1.83  | 1.98  | 2.35  | 2.1–2.6      |
| Phosphate (mmol/L) | 0.45  | 1.42  | 0.90  | 0.97  | 1.32  | 1.19  | 1.1–2.0        |

| Phosphate formulation (10 ml orally five times a day) | Beginning of drug administration | Break | + | + | + | Termination of drug administration |

In bold abnormal concentrations of calcium and phosphate.
although some authors have reported the use of doses of single phosphate dosage of 0.24 mmol/kg body weight, whereas a dosage of 0.16 mmol/kg body weight is recommended for short-term uncomplicated hypophosphatemia. Some manufacturers recommend a maximum temia, whereas a dosage of 0.16 mmol/kg body weight is recommended for short-term uncomplicated hypophosphatemia. Patients with renal failure are prone to developing hypophosphatemia. The recommended oral dosage of phosphate is 30–40 mg Pi/kg of body weight every 24 h, administered in four to five doses [3, 31, 32]. It is important to note that diarrhea is one of the effects of oral phosphate overdose, which can contribute to further electrolyte imbalance. Our patient received higher doses (62 mg Pi/kg body weight over 24 h) with good tolerance.

Intravenous administration of phosphate solution should be used for critically ill patients and those who are nil by mouth. Both potassium and sodium phosphates are available. These should be administered together with sodium chloride or glucose solutions, as low-soluble salt would precipitate in solutions containing calcium. High dose or rapid phosphate infusion may lead to hypophosphatemia, hypotension, hypocalcaemia with tetanus, renal failure and ECG abnormalities. Most of the data about dosage has come from research on adults, thus each case must be approached with caution. A dosage of 0.08 mmol/kg body weight every 6 h is recommended for short-term uncomplicated hypophosphatemia, whereas a dosage of 0.16 mmol/kg body weight is advised for long-term hypophosphatemia of complex origin. Some manufacturers recommend a maximum single phosphate dosage of 0.24 mmol/kg body weight, although some authors have reported the use of doses of 0.4–0.5 mmol/kg body weight every 6 h in specific conditions, up to a maximum dose of 50 mmol. Doses should be individually adjusted to the patient’s clinical condition, hypophosphatemia severity, and their reaction to phosphate infusion [3, 6, 32, 33].

**Conclusions**

It is recommended that blood calcium and phosphate levels be carefully monitored in DKA patients in a serious condition. The blood phosphate level decreases after the initiation of DKA treatment, which is potentiated by insulin. Clinical symptoms usually occur at a blood phosphate level lower than 0.32 mmol/L, although the intracellular phosphate level also plays a crucial role. Hypophosphatemia commonly appears on the second day of treatment, thus it is vital to monitor ECG. Severe hypophosphatemia with clinical symptoms requires oral or intravenous supplementation of phosphate. So far, there is no evidence of any benefits of routine administration of phosphate in patients with DKA. Patients with DKA who are at risk for hypophosphatemia include those with low blood pH, extremely high blood glucose level and very low BE, nil by mouth patients who have received intravenous insulin for longer than 24 h, cachectic or malnourished patients, and those with a vitamin D deficiency.

**Table 3** Phosphate and vitamin D supplementation in severe acute hypophosphatemia

| Oral phosphate salts at a dose of 30–40 mg/kg body weight per day, administered in 4–5 doses. |
| Cholecalciferol (vitamin D3) at a dose of 800–1000 U/day (increase the dose in case of deficiency). |
| Intravenous phosphate solution at the following doses: |
| - 0.08 mmol/kg body weight for 6 h, recommended for short-term hypophosphatemia without complications; |
| - 0.16 mmol/kg body weight for long-term hypophosphatemia; or |
| - In some cases, doses up to 0.4–0.5 mmol/kg body weight for 6 h are required, up to a maximum dose of 50 mmol of phosphate. |

**Abbreviations**

2,3-DPG: 2,3-Diphosphoglycerate; ATP: Adenosine triphosphate; BE: Base excess; DKA: Diabetic ketoacidosis; ECG: Electrocardiography; LBBB: Left bundle branch block; PTH: Parathormone; PTHrP: Parathyroid hormone-related protein; PVC: Premature Ventricular Contractions; SVT: Supraventricular tachycardia

**Acknowledgements**

Not applicable.

**Funding**

Medical University of Lublin DS 415.

**Availability of data and materials**

The datasets generated during and/or analysed during the current study “Ventricular bigeminy and trigeminy caused by hypophosphatemia during diabetic ketoacidosis treatment: a case report” are available from the corresponding author on reasonable request.

**Authors’ contributions**

KM- Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content. JMW- Drafting the work or revising it critically for important intellectual content. RP- Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work. BWL- Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work Rj- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. IBS- Drafting the work or revising it critically for important intellectual content; AND Final approval of the version to be published. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.
References

1. ISPAD. Clinical practice consensus guidelines 2018: diabetic ketoacidosis and the hyperglycemic hyperosmolar state. Pediatr Diabetes. 2018;19(Suppl 27):155–77.

2. Geerse DA, Bindels AJ, Kuiper MA, Roos AN, Sprank P. Treatment of hypophosphatemia in the intensive care unit: a review. Crit Care. 2010;14(147).

3. Allgrove J, Shaw N, editors. Calcium and bone disorders in children and adolescents. 2nd ed. Basel: Karger; 2015. p. 174-51. Endocr Dev 4.

4. Kligeman RM, Stanton BMD, Schor NF, Behrman RE. Nelson textbook of pediatrics. 20th ed. Philadelphia: Elsevier; 2015.

5. Assadi F. Hypophosphatemia: an evidence-based problem-solving approach to clinical cases. Iran J Kidney Dis. 2010;4(2):195–201.

6. Bugg NC, Jones JA. Hypophosphataemia. Pathophysiology, effects and management on the intensive care unit. Anaesthesia. 1998;53(9):895–902.

7. Guest G. Organic phosphates of the blood and mineral metabolism in diabetic acidosis. Am J Dis Child. 1942;64:401–12.

8. Guest G. Rapoport S. Electrolytes of blood plasma and cells in diabetic acidosis and during recovery. Proc Amer Diab Assoc. 1947;7:95–115.

9. Shen T, Braude S. Changes in serum phosphate during treatment of diabetic ketoacidosis: predictive significance of severity of acidosis on presentation. Intern Med J. 2012;42(12):1347–50.

10. Jacob R, Patel RS, Fuentes F. Less phosphorus, more problems: hypophosphatemia induced polymorphic ventricular tachycardia in a young male. Int J Clin Cardiol. 2018;5:112.

11. de Oliveira Iglesias SB, Pons Leite H, de Carvalho WB. Hypophosphatemia-induced seizure in a child with diabetic ketoacidosis. Pediatr Emer Care. 2002;20:859–61.

12. Ariyoshi N, Nogi M, Ando A, Watambe H, Umekawa S. Cardiovascular consequences of hypophosphatemia. Panminerva Med. 2017;59:230–40.

13. Choi HS, Kwon A, Che W, Suh J, Kim DH, Kim H-S. Respiratory failure in a diabetic ketoacidosis patient with severe hypophosphatemia. Ann Pediatr Endocrinol Metab. 2018;23:103–6.

14. Konstantinov NK, Röhrheib M, Gabia El, Dorin R, Murata GH, Tzamaloukas AH. Respiratory failure in diabetic ketoacidosis. World J Diabetes. 2015;6(8):1009–23.

15. Guidelines on the management of diabetic patients. A position of Diabetes Poland. Clin Diabet. 2018;7:1–94.

16. Malik M, Batchvarov VN. Measurement, interpretation and clinical potential of QT dispersion. J Am Coll Cardiol. 2000;36(6):1749–66.

17. Postema PG, Wilde AAM. The measurement of the QT interval. Curr Cardiol Rev. 2014;10(3):287–94.

18. Zieg J, Gonzorikova L, Landau D. Current views on the diagnosis and management of hypokalaemia in children. Acta Paediatr. 2016;105(7):762–72.

19. Surawicz B. Electrolytes and the electrocardiogram. Am J Cardiol. 1963;12(5): 656–62.

20. Salkawa T, Tsumabuki S, Nakagawa M, Takakura T, Tamura M, Maeda T, Ito S, Ito M. QT intervals as an index of high serum calcium in hypercalcaemia. Clin Cardiol. 1988;11(2):75–8.

21. Riley MS, Schade DS, Eaton PR. Effect of insulin infusion on plasma phosphate in diabetic patients. Metabolism. 1979;28(3):191–4.